Our observations in clinical specimens demonstrated that vimentin expression is related to poor outcomes in naïve ALK-rearranged NSCLC patients, indicating that a novel therapeutic strategy is required for these patients. This evidence concerns the gene VIM and non-small cell lung carcinoma.